Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity: 2019-2025

Historic Common Equity for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$1.9 billion.

  • BridgeBio Pharma's Common Equity fell 58.57% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 58.57%. This contributed to the annual value of -$1.5 billion for FY2024, which is 8.39% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Common Equity stood at -$1.9 billion, which was down 8.12% from -$1.8 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Common Equity registered a high of -$389.4 million during Q1 2021, and its lowest value of -$1.9 billion during Q3 2025.
  • Moreover, its 3-year median value for Common Equity was -$1.3 billion (2023), whereas its average is -$1.4 billion.
  • As far as peak fluctuations go, BridgeBio Pharma's Common Equity crashed by 915.96% in 2021, and later climbed by 19.86% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Common Equity (Quarterly) stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then decreased by 8.92% to -$1.4 billion in 2023, then fell by 8.39% to -$1.5 billion in 2024, then tumbled by 58.57% to -$1.9 billion in 2025.
  • Its Common Equity stands at -$1.9 billion for Q3 2025, versus -$1.8 billion for Q2 2025 and -$1.6 billion for Q1 2025.